Current Diagnostic Strategies and Overview of Preimplantation, Prenatal
and Postnatal DNA Diagnostics of Cystic Fibrosis in the Czech Republic
Balaščaková M.1*, Piskáčková T.1*, Holubová A.1, Raušová E.1, Kazárová V.1, Krebsová A.1, Koudová M.1, Štambergová A.1, Čamajová J.1, Norambuena P.1, Křenková P.1, Votava F.2, Skalická V.3, Vávrová V.3, Macek M. st.1, Macek M. ml.1
Ústav biologie a lékařské genetiky UK 2. LF a FN Motol, Praha1 přednosta prof. MUDr. M. Macek ml., DrSc. Klinika dětí a dorostu UK 3. LF a FN Královské Vinohrady, Praha2 přednosta doc. MUDr. F. Votava, PhD. Pediatrická klinika UK 2. LF a FN Motol, Praha3 přednosta prof. MUDr. J. Lebl, CSc. |
|
Summary:
Cystic fibrosis (CF) is the most common autosomal recessive and potentially lethal
disorder, caused by mutations in the CFTR gene. The disease’s incidence has been estimated
to approximately 1 per 2700–3800 newborns in the Czech Republic, which means
that every 26th–33rd individual is a healthy carrier of a mutation in the CFTR gene.
Early diagnosis by the first two months of life is considered as a favourable prognostic
factor. Moreover, a reliable molecular genetic analysis is able to confirm clinical
diagnosis of CF. Subsequently, specialised genetic counselling is recommended. The
aim of genetic counselling in CF is to provide comprehensible information about the
heredity of this disease and to offer carrier testing in direct family members and/or relatives of the index case. Within the frame of preconception care we inform couples
about the possibilities of CF prenatal diagnosis. The main purpose of the molecular
genetic examination is to provide a choice of a healthy child, not affected by CF.
Key words:
cystic fibrosis (OMIM 219700), CFTR gene, prenatal diagnosis, postnatal
diagnosis, newborn screening, mutations, variants, genetic modifiers, preimplantation
genetic diagnosis
|